Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
about
A snapshot of gene therapy in Latin AmericaEndoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccinesA DNA Vaccine Formulated with Chemical Adjuvant Provides Partial Protection against Bovine Herpes Virus Infection in CattleSurgical immune interventions for solid malignancies.Combined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infectionPreclinical and clinical development of DNA vaccines for prostate cancer.Helminth coinfection does not affect therapeutic effect of a DNA vaccine in mice harboring tuberculosis.Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the artTherapeutic cancer vaccines: are we there yet?Immunotherapy for head and neck cancer: advances and deficiencies.Systemic therapy strategies for head-neck carcinomas: Current statusTrial watch: DNA vaccines for cancer therapy.The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy.Novel targeted therapies in head and neck cancer.Mycobacterial Hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients.HSP60: issues and insights on its therapeutic use as an immunoregulatory agent[Immunotherapy of head and neck cancer. Current developments].Recombinant DNA immunotherapy ameliorate established airway allergy in a IL-10 dependent pathway.Antigen-specific immunotherapy in head and neck cancer
P2860
Q26998837-64D97E05-9F3D-4CFD-918E-8ABEBC0DFEE1Q28084299-3A4A2330-C935-4BC4-9C63-6D03F0806546Q28818326-C756DE44-C5D9-446B-BA7D-F43EC429149CQ30393261-404FC662-A523-48AA-B8FA-2FC4499AF6FEQ30578697-74D29DF6-3C39-471D-849B-4752ED7D7F9AQ33740811-97D3F900-14CA-403B-B65D-4C689E049CB8Q33900309-605B18FB-CACA-4329-9FC7-A1C3734C5B39Q33907628-A30147F3-F210-456C-A91E-ED85E490006DQ34786691-7929D46D-8077-47F1-B1A4-372ACA80DF00Q35072040-B61147EF-B27D-44C3-8A33-28B8E7B9A2EBQ36529843-B0C134BB-AF14-439E-A8ED-E7A669E05B12Q36845824-2FA2B268-72B4-46CE-AE95-89549FD2400CQ37825430-3A1570CC-2E6D-436A-9FD0-E1FAB71A0FAFQ37975224-C37641C9-9A4D-4F26-8E4E-2BB9068712DBQ40383030-B1A27DDC-81A5-4EE3-A50A-3DFB32F929C4Q42102746-703EF282-6F53-4277-83F5-C12B6FA34A7CQ45770749-046BC632-C309-4A40-A90D-02166037E9E4Q50507569-64BC5ECF-1963-4E86-BED0-FAC0934065BEQ58146388-81FED80B-F69E-4A28-9477-59AE9BD602D5
P2860
Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Immune response to vaccination ...... head and neck cancer patients.
@en
type
label
Immune response to vaccination ...... head and neck cancer patients.
@en
prefLabel
Immune response to vaccination ...... head and neck cancer patients.
@en
P2093
P2860
P356
P1433
P1476
Immune response to vaccination ...... head and neck cancer patients.
@en
P2093
A Socorro-Silva
G D Victora
K Abdallah
P Michaluart
R A Moyses
P2860
P2888
P304
P356
10.1038/CGT.2009.9
P577
2009-02-06T00:00:00Z
P5875
P6179
1007553632